Institutional investors purchased a net $605.8 thousand shares of EBS during the quarter ended March 2016. This may signal that the smart money is gaining interest in this company as the 86.72% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ABERDEEN ASSET MANAGEMENT, INC. Bought 22.0 Thousand shares of Emergent BioSolutions Inc